Catalog No.
Product Name
Application
Product Information
Citations
-
Anti-Inflammatory Agent
Desmethyl Ketoprofen is an anti-inflammatory agent that primarily targets pathways involved in inflammation modulation. It exhibits significant anti-inflammatory activities, making it valuable for research in angiogenesis-related disorders and associated pathologies. This compound is essential for studies investigating the effects of inflammation on tissue repair and vascular dynamics. -
Anti-inflammatory Agent
2′-Hydroxydihydrochalcone is an anti-inflammatory agent that exerts its effects through the modulation of inflammatory pathways. This compound is particularly valuable in research investigating mechanisms of inflammation and potential therapeutic applications for inflammatory diseases. It can be synthesized via the reduction of flavone, highlighting its utility in chemical biology studies. -
COX Inhibitor
1-Oxo Ibuprofen is a cyclooxygenase (COX) inhibitor, specifically targeting COX-1 and COX-2 enzymes. As a degradation product and potential impurity of Ibuprofen, it demonstrates significant anti-inflammatory activity with IC50 values of 13 μM for COX-1 and 370 μM for COX-2. This compound is useful for research applications involving the study of prostaglandin synthesis and the metabolic pathways of nonsteroidal anti-inflammatory drugs. -
Anti-inflammatory Agent
6-trans-12-epi-Leukotriene B4, a metabolite of arachidonic acid, functions primarily as an anti-inflammatory agent. Its biological activity is attributed to its role in modulating leukocyte recruitment and activation. This compound is commonly utilized in research applications focused on inflammation, immune response, and related signaling pathways. -
Drug Metabolite
Carvedilol Glucuronide is a significant metabolite of the β/α-1 adrenergic receptor antagonist, Carvedilol. This compound demonstrates key biological activity by modulating β-adrenergic signaling and exhibits potential application in studying the metabolic pathway of Carvedilol. Research indicates that Carvedilol can inhibit lipid peroxidation and has properties as an antihypertensive agent, as well as an autophagy inducer that affects the NLRP3 inflammasome. Carvedilol Glucuronide serves as an important reagent for investigating drug metabolism and pharmacokinetics in cardiovascular research. -
ERAP1 Inhibitor
ERAP1 modulator-2 is a potent inhibitor of the enzyme ERAP1, exhibiting an IC50 value of less than 100 nM. This compound effectively modulates the activity of ERAP1, influencing peptide trimming and presentation in the context of antigen processing. It is valuable for research applications focused on immune regulation, inflammation, and the modulation of major histocompatibility complex (MHC) class I-mediated responses. -
Anti-inflammatory Agent
4-MDM (4-Methoxydiphenylmethane) is an orally active anti-inflammatory agent that selectively enhances the activity of the enzyme leukotriene A4 hydrolase (LTA4H) by promoting its aminopeptidase function. This modulation reduces neutrophil recruitment in the lungs through the improved degradation of proline-glycine-proline, leading to a decrease in inflammation. Importantly, 4-MDM does not influence the epoxy-hydrolase activity of LTA4H. This compound is suitable for studies focusing on lung diseases and related inflammatory conditions. -
Anti-inflammatory Agent, Aminopeptidase Inhibitor
2-(2'-Pyridyl)benzimidazole is an effective anti-inflammatory agent and a potent inhibitor of methionine aminopeptidase in Escherichia coli. This compound exhibits tridentate ligand properties, capable of forming stable complexes with various transition metal ions. Its applications extend to biochemical research focused on inflammatory processes and amino acid metabolism, making it a valuable reagent for studies in these areas. -
Keap1/Nrf2 Inhibitor
PRL-295 is an orally active inhibitor targeting the interaction between Keap1 and Nrf2. By enhancing the thermal stability of Keap1, PRL-295 disrupts its binding to Nrf2, leading to the activation of Nrf2-dependent genes such as NAD(P)H:quinone oxidoreductase 1 (NQO1). This compound has demonstrated protective effects against Acetaminophen-induced liver injury in murine models, making it a valuable tool for research into oxidative stress and related pathologies. -
Nrf2/AMPK/mTOR Activator
Hydroxycitric acid is an orally active compound that serves as a multifunctional activator of Nrf2, AMPK, and mTOR pathways. It enhances the expression of antioxidant enzymes, such as superoxide dismutase, and increases glutathione levels, thereby mitigating oxidative stress and ferroptosis, particularly in renal tubular epithelial cells. Additionally, hydroxycitric acid induces cell cycle arrest in cancer cells and promotes DNA fragmentation through modulation of the AMPK and mTORC1/S6K signaling pathways. This compound is valuable for research in oxidative stress, cancer biology, and metabolic regulation. -
ACOX1 Inhibitor
10,12-Tricosadiynoic acid is a selective and potent inhibitor of acyl-CoA oxidase-1 (ACOX1). It demonstrates significant potential in addressing metabolic disorders induced by high-fat diets or obesity by enhancing mitochondrial lipid metabolism and modulating reactive oxygen species (ROS) levels. Additionally, this compound serves as a versatile click chemistry reagent, featuring an alkyne group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, making it valuable for various biochemical applications. -
P2X4 Inhibitor
NP-1815-PX sodium is a selective inhibitor targeting the P2X4 receptor, exhibiting an IC50 of 0.26 μM against human P2X4 receptors. This compound effectively inhibits ATP-mediated prostaglandin production and attenuates TP receptor-induced calcium elevation, as well as NLRP3 inflammasome signaling. Notably, NP-1815-PX sodium demonstrates anti-allodynic effects in vivo and alleviates DNBS-induced colitis symptoms, including weight loss and tissue damage, through the downregulation of IL-1β levels and Caspase-1 activity. This reagent is applicable in research areas such as asthma and inflammatory bowel disease. -
TASK-3 Agonist/TWIK2 Blocker
NPBA is a potassium K2P channel TASK-3 (KCNK9) agonist and TWIK2 (KCNK1) channel blocker. This compound plays a crucial role in inhibiting NLRP3 inflammasome activation in macrophages, making it valuable for research into inflammatory pathways and potassium channel function. Its unique mechanism provides insights into potential therapeutic applications in inflammatory diseases. -
Anti-inflammatory Lipid Mediators
5,6-DiHETE is an anti-inflammatory lipid mediator that is synthesized from eicosapentaenoic acid (EPA). It plays a crucial role in mitigating vascular hyperpermeability during inflammatory responses, making it a valuable tool in the study of various inflammatory diseases. Researchers utilize 5,6-DiHETE to explore its therapeutic potential and elucidate the underlying mechanisms of inflammation. -
Anti-inflammatory Agent
Tiaramide is an anti-inflammatory agent that exerts its effects by inhibiting the release of prostaglandin E2 (PGE2). This compound also prevents the increase in intracellular free calcium levels induced by PGE2 and bradykinin, thereby mitigating bradykinin-induced contraction. Tiaramide is valuable for research applications focused on inflammatory pathways and calcium signaling in cellular models. -
Anti-inflammatory Agent
LQFM020 is an orally active pyrazole derivative that functions as an anti-inflammatory agent. It effectively inhibits calcium channels while activating potassium and nitric oxide/cGMP pathways, leading to reduced vasoconstriction. LQFM020 exhibits significant anti-inflammatory and analgesic properties, making it a valuable reagent for research focused on inflammation and pain mechanisms. -
Anti-inflammatory Agent
Trepibutone is an anti-inflammatory agent that enhances the secretion of bile and pancreatic juice while promoting smooth muscle flaccidity in the gastrointestinal tract. This compound serves as a valuable tool in the study of cholecystitis and various functional gastrointestinal disorders, providing insights into digestive health and inflammation-related conditions. -
Anti-inflammatory Agent
Resolvin E2, a proresolving lipid mediator, functions primarily as an anti-inflammatory agent. It plays a crucial role in resolving inflammation and promoting tissue repair through its influence on immune cell activities. This compound is utilized in research applications focused on inflammation resolution, chronic inflammatory diseases, and the modulation of immune responses. -
Anti-inflammatory Agent
LY269415 is a potent anti-inflammatory agent that acts as an inhibitor of iron-dependent lipid peroxidation and 5-lipoxygenase enzyme activity. This compound exhibits significant antioxidant properties, making it valuable for research focused on inflammatory pathways and related diseases. Its oral bioavailability allows for versatile applications in preclinical studies aimed at understanding inflammation-related mechanisms and potential therapeutic interventions. -
LXR Agonist
DMHCA is a potent and selective liver X receptor (LXR) agonist that specifically activates the cholesterol efflux pathway while avoiding the stimulation of triglyceride synthesis. This compound exhibits anti-inflammatory properties, making it a valuable tool for research in cholesterol homeostasis and diabetes. DMHCA's selective mechanism provides insight into the role of LXR modulation in metabolic disorders. -
MALT1 Protease Inhibitor
Safimaltib is a potent and selective allosteric inhibitor of MALT1 protease. It exhibits significant biological activity by hindering MALT1's function, which may contribute to tumor stasis in various cancer models. This compound is valuable for research applications exploring the role of MALT1 in oncogenesis and potential therapeutic interventions in malignancies driven by aberrant MALT1 activity. -
MALT1 Inhibitor
MLT-985 is a selective allosteric inhibitor of MALT1, demonstrating an IC50 value of 3 nM. This compound effectively suppresses cell proliferation and intervenes in aberrant signaling associated with the CARD11/BCL10/MALT1 complex. MLT-985 is applicable in research focused on cancer, particularly in the study of B cell malignancies. -
MALT1 PROTAC Degrader
PROTAC MALT1 Degrader-1 is a selective degrader targeting MALT1 through the use of the PROTAC (proteolysis targeting chimera) technology. This compound facilitates the ubiquitination and subsequent proteasomal degradation of MALT1, making it a valuable tool for studies focused on lymphoma and related malignancies. Its mechanism of action enables the investigation of MALT1's role in cellular processes and therapeutic strategies for lymphoma treatment. -
MALT1 Protease Inhibitor
MLT-943 is a selective and orally active inhibitor of MALT1 protease. It effectively inhibits stimulated IL-2 secretion in peripheral blood mononuclear cells (PBMC) and whole blood, demonstrating consistent IC50 values across species (0.07-0.09 μM in PBMC and 0.6-0.8 μM in whole blood). With its notable anti-inflammatory properties, MLT-943 is a valuable reagent for investigating FcγR-mediated inflammatory processes. -
MALT1 Inhibitor
Z-VRPR-FMK is an irreversible inhibitor of the MALT1 protein. It effectively inhibits the growth and invasion of diffuse large B-cell lymphoma by blocking MALT1-induced NF-κB activation and matrix metalloproteinase (MMP) expression. This makes Z-VRPR-FMK a valuable tool for research investigating the role of MALT1 in oncogenesis and therapeutic strategies targeting NF-κB pathways. -
MALT1 Inhibitor
MLT-231 is a potent allosteric inhibitor of MALT1, demonstrating high selectivity with an IC50 of 9 nM. This compound effectively prevents the cleavage of endogenous BCL10, with an IC50 of 160 nM. MLT-231 shows promising antitumor activity in mouse models of activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL), making it a valuable tool for research into therapeutic strategies targeting MALT1-related pathways. -
MALT1 Inhibitor
MALT1-IN-11 is a potent MALT1 protease inhibitor with an IC50 of less than 10 nM. This compound effectively inhibits interleukin-10 (IL-10) secretion, with an IC50 range of 10-100 nM. MALT1-IN-11 is utilized in research focused on cancer, autoimmune diseases, and inflammatory disorders, providing valuable insights into the role of MALT1 in these pathological conditions. -
MALT1 Protease Inhibitor
MALT1-IN-9 is a selective MALT1 protease inhibitor, demonstrating an IC50 of less than 500 nM in Raji MALT1-GloSensor cells. This compound exhibits significant anticancer activity, making it a valuable tool for research focused on targeting MALT1 in various oncological studies. Its efficacy supports investigations into the role of MALT1 in cancer progression and therapeutic development. -
MALT1 Inhibitor
MALT1-IN-5 is a potent inhibitor of the MALT1 protease, targeting the NF-κB signaling pathway. This compound has demonstrated significant biological activity in disrupting MALT1-dependent signaling processes. MALT1-IN-5 is primarily utilized in cancer research to investigate the role of MALT1 in tumorigenesis and its potential as a therapeutic target. -
MALT1 Protease Inhibitor
(R)-MALT1-IN-7 is a selective MALT1 protease inhibitor, designed for investigating the role of MALT1 in various biological processes. It exhibits potent inhibitory activity, making it valuable for cancer research, particularly in studies exploring the underlying mechanisms of tumorigenesis and potential therapeutic interventions. This compound serves as a useful tool in elucidating the function of MALT1 in both normal and pathological cellular contexts. -
MALT1 Inhibitor
MALT1-IN-3 is a selective MALT1 protease inhibitor with a potent IC50 of 0.06 μM. This compound demonstrates inhibitive effects on human IL-6 and IL-10 production in OCI-LY3 cells, exhibiting IC50 values of 0.14 μM and 0.13 μM, respectively. MALT1-IN-3 is valuable for research into gene expression regulation, immune response modulation, and potential therapeutic strategies in various malignancies. -
MALT1 Inhibitor
(R)-MLT-985 is a selective allosteric inhibitor of MALT1, exhibiting an IC50 value of 3 nM. This compound effectively suppresses cell proliferation and disrupts aberrant signaling initiated by the CARD11/BCL10/MALT1 complex. (R)-MLT-985 is primarily utilized in research related to cancer, particularly in the study of B cell malignancies. -
MALT1 Inhibitor
NVS-MALT1 is an allosteric inhibitor of the MALT1 protein, disrupting its activity and providing a valuable tool for studying MALT1-mediated signaling pathways. This compound demonstrates the ability to modulate NF-κB activation and enhance apoptosis in cancer cells, making it relevant for research in oncology and immune response. It is particularly useful in investigations focusing on B-cell lymphoma and other MALT1-associated diseases. -
MALT1 Inhibitor
Ocipumaltib is a potent inhibitor of mucosa-associated lymphoid tissue protein 1 (MALT1), which plays a crucial role in various signaling pathways. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Additionally, Ocipumaltib is applicable in the study of infection, neurological disorders, and hematological diseases, providing insights into MALT1's involvement in these conditions. -
MALT1 Inhibitor
(S)-MALT1-IN-5 is a potent inhibitor targeting the MALT1 protease. This compound effectively inhibits MALT1 activity, which may provide therapeutic insights for conditions associated with aberrant T cell receptor and B cell receptor signaling, as well as cancers and inflammatory diseases linked to MALT1 dysregulation. (S)-MALT1-IN-5 is a valuable tool for researching MALT1-related disease mechanisms and developing potential interventions. -
MALT1 Inhibitor
Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone is a potent inhibitor of MALT1, a key protein involved in various signaling pathways. This compound effectively inhibits cell proliferation and migration, demonstrating significant anticancer activity. It is valuable for research applications focused on cancer biology and therapeutic strategies targeting MALT1-related pathways. -
MALT1 Protease Inhibitor
MALT1-IN-8 is a potent inhibitor of MALT1 protease, demonstrating an IC50 of 2 nM. This compound effectively inhibits the proliferation of OCI-LY3 lymphoma cells, with an IC50 value of 1.16 μM. MALT1-IN-8 shows potential for anticancer applications, making it a valuable tool for research in lymphoma and other malignancies involving MALT1. -
MALT1 Protease Inhibitor
(R)-MALT1-IN-3 is a selective MALT1 protease inhibitor, exhibiting a potent IC50 of 20 nM. Additionally, this compound demonstrates significant inhibition of interleukin-6 and interleukin-10 with IC50 values of 60 nM and 40 nM, respectively, in OCI-LY3 cells. It serves as a valuable tool for exploring the role of MALT1 in various biological processes, particularly in the context of inflammatory pathways and cancer research. -
MALT1 Protease Inhibitor
MALT1-IN-6 is a selective inhibitor of MALT1 protease, exhibiting a Ki value of 9 nM. This compound demonstrates significant anticancer activity, making it a valuable tool for research focused on cancer therapeutics and the study of signaling pathways modulated by MALT1. Its potency and specificity may facilitate investigations into the roles of MALT1 in various malignancies. -
MALT1 Inhibitor
RGT-068A is a selective and orally bioavailable inhibitor of MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1). This compound demonstrates potent inhibitory activity against MALT1, which is essential for NF-κB signaling in various hematological malignancies and inflammatory diseases. RGT-068A serves as a valuable tool for research into therapeutic strategies targeting MALT1 in cancer and autoimmune disorders. -
MALT1 Protease Inhibitor
MALT1-IN-7 is a potent inhibitor of the MALT1 protease, which plays a crucial role in various oncogenic signaling pathways. Its ability to selectively inhibit MALT1 makes it a valuable tool for investigating the mechanisms underlying cancer development and progression. This compound is particularly relevant for research applications focused on tumor biology and therapeutic strategies targeting MALT1-dependent pathways. -
MALT1 Inhibitor
MALT1-IN-14 is a potent MALT1 inhibitor, exhibiting an IC50 value of 0.081 μM. This compound demonstrates significant inhibition of MALT1's protease activity, making it valuable for studies investigating the role of MALT1 in inflammatory responses and lymphocyte activation. Its application extends to research in various diseases, including hematological malignancies and autoimmune disorders. -
Anti-inflammatory Agent
Clidanac is a potent anti-inflammatory agent that acts by uncoupling oxidative phosphorylation. This mechanism contributes to its role in modulating inflammatory responses. Clidanac is primarily applied in research focused on conditions such as rheumatoid arthritis, making it a valuable tool for studying inflammation pathways and potential therapeutic interventions. -
Anti-Inflammatory Peptide
Collagen Type II Fragment is an anti-inflammatory peptide that effectively inhibits collagen-induced arthritis (CIA) in murine models. This fragment serves as a valuable tool for studying inflammation and immune responses, facilitating research aimed at understanding and developing therapies for autoimmune conditions. -
HIF Inhibitor
Arylsulfonamide 64B is a potent inhibitor of hypoxia-inducible factor (HIF). This compound effectively suppresses hypoxia/HIF-mediated expression of key oncogenes such as c-Met and CXCR4, thereby demonstrating significant anti-tumor activity. Arylsulfonamide 64B is particularly relevant for research focused on uveal melanoma, as it has been shown to reduce primary tumor growth and metastasis in mouse models. -
Anti-inflammatory Agent
Linalyl acetate is a phytochemical compound that primarily functions as an anti-inflammatory agent. It exhibits a range of biological activities including anti-anxiety and cardioprotective effects. This compound is useful in research focusing on inflammatory responses and offers potential applications in developing therapeutic agents for related conditions. Linalyl acetate's oral bioactivity further enhances its relevance in pharmacological studies. -
Endogenous Metabolite
9(R)-HODE is a monohydroxy fatty acid and an endogenous metabolite of linoleic acid, generated through the enzymatic actions of cyclooxygenase (COX) and lipoxygenase (LO). This compound is known to promote chemotaxis and elevate the expression of chemokine receptors CCR9 and CXCR4 in immune cells. Additionally, 9(R)-HODE effectively inhibits interleukin-6 (IL-6) release in primary human monocytes and suppresses CD3α- and CD28-induced proliferation in isolated human peripheral blood lymphocytes at a concentration of 25 μg/mL, making it a valuable tool for studying immune responses and inflammatory processes. -
Anti-Inflammatory Agent
3-Aminoisobutyric acid sodium salt acts as an anti-inflammatory agent through its antioxidant properties. It enhances the expression of brown adipocyte-specific genes within white adipose tissue and promotes fatty acid β-oxidation in hepatocytes. This compound has been shown to mitigate insulin resistance and inflammation triggered by palmitate or high-fat diets via an AMPK–PPARδ-dependent pathway in murine models. Additionally, 3-Aminoisobutyric acid sodium salt is a catabolic metabolite of thymine and valine in skeletal muscle. -
PGE2 Product
13,14-Dihydro-15-keto-prostaglandin A2 is a derivative of 13,14-dihydro-15-keto PGE2, resulting from the non-enzymatic dehydration process. This compound is primarily involved in the metabolic pathway leading to the formation of bicyclo PGE2, which serves as a critical biomarker for PGE2 synthesis. Its significant role in prostaglandin metabolism makes it valuable for research in inflammation, pain, and various physiological processes associated with prostaglandins. -
Anti-inflammatory Agent
17(R)-Resolvin D1 methyl ester serves as a potent anti-inflammatory agent, derived from Aspirin-induced Resolvin D1. This compound is known to regulate the transendothelial migration of human polymorphonuclear leukocytes, displaying significant efficacy with an EC50 of approximately 30 nM for inhibiting neutrophil migration. Its stability as the 17R-trihydroxy-4Z form enhances its utility in inflammation research and therapeutic applications.
